Patents Examined by Yong S. Chong
  • Patent number: 11447831
    Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: September 20, 2022
    Assignee: Syros Pharmaceuticals, Inc.
    Inventors: Mei Wei Chen, Cindy Collins, Matthew Lucas Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael Robert McKeown, David A. Orlando
  • Patent number: 11447646
    Abstract: Presented are compositions that can be used as protective coatings for agricultural (e.g., food) substrates. The compositions can comprise a compound of Formula I: and an additive, wherein the variables m, n, q, r, Ra, Rb, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are defined herein. The protective coatings formed from the compositions can be used to prevent food spoilage due to, for instance, moisture loss, oxidation, or infection by a foreign pathogen.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: September 20, 2022
    Assignee: Apeel Technology, Inc.
    Inventors: Louis Perez, Chance Holland, James Rogers, Stephen William Kaun, Carlos Hernandez, Charles Patrick Frazier
  • Patent number: 11446285
    Abstract: Methods for treating systemic lupus erythematosus (SLE) are disclosed, based on administering to a subject with SLE an amount effective to treat the subject of a polypeptide including antiogensin 1-7 (A(1-7)), Nle3A 1-7, or a compound according to general formula.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: September 20, 2022
    Assignee: University of Southern California
    Inventors: Maira Soto, Kevin J. Gaffney, Kathleen E. Rodgers
  • Patent number: 11444253
    Abstract: A thermally activated delayed fluorescent material includes a compound having structural formula (I) as follows: A-D??(I). A is an electron acceptor and D is an electron donor. In addition, a method of preparing a thermally activated delayed fluorescent material and an organic light emitting diode display device using the thermally activated delayed fluorescent material as luminescent host material are provided. The organic light emitting diode display device includes an anode, a cathode, and an organic functional layer disposed between the anode and the cathode. The organic functional layer includes the thermally activated delayed fluorescent material having a structural formula (I).
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: September 13, 2022
    Assignee: Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd.
    Inventor: Bo Wang
  • Patent number: 11434235
    Abstract: Disclosed are a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid, a preparation method therefor, a pharmaceutical composition comprising same, and the use thereof in the preparation of drugs for preventing or treating viral diseases.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: September 6, 2022
    Inventors: Tianming Wang, Chengxi Yang, Jiaqiang Cai, Wei Liu, Baolei Zhang, Qiang Tian, Shuai Song, Hao Hu, Weibiao Han, Youqiang Li, Xing Chen, Lichun Wang, Jingyi Wang
  • Patent number: 11414377
    Abstract: The invention relates to organic chemistry, pharmacology and medicine and is concerned with the treatment of inflammatory and autoimmune diseases, such as psoriasis, atopic dermatitis, prurigo, Crohn's disease, colitis, gastrointestinal diseases such as diarrhoea and irritable bowel syndrome, respiratory diseases such as asthma, COPD, bronchitis, rhinitis, and also cough and a series of other diseases associated with the activity of opioid and tachykinin receptors and of TRPV1 and TRPM8 ion channels using a 2-phenylethylamine N-(p-hydroxyphenylacetyl)phenylalanine compound The invention, and also pharmaceutically acceptable adducts, hydrates, solvates are agonists of opioid receptors, antagonists of tachykinin receptors and of TRPV1 and TRPM8 ion channels. The invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of the compound according to the invention.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: August 16, 2022
    Inventor: Vladimir Evgenievich Nebolsin
  • Patent number: 11406617
    Abstract: The present invention provides compounds for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 9, 2022
    Assignee: Intervet Inc.
    Inventors: Thorsten Meyer, Ralf Warrass, Joachim Ullrich, Michael Berger, Michael Linder
  • Patent number: 11407831
    Abstract: A pharmaceutical composition including a compound represented by the formula (I) or a pharmacologically acceptable salt thereof wherein two R moieties each independently are a C1-3 alkyl group or are groups bonded to each other to form a C2-5 alkylene group; A is an optionally substituted C6-10 aryl group or an optionally substituted heteroaryl group; and R1, R2 and R3 each independently are an optionally substituted linear or branched C1-4 alkyl group, wherein the pharmaceutical composition is administered in combination with an immunotherapeutic agent.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 9, 2022
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Yasuhiro Aga, Sayaka Ogi
  • Patent number: 11395811
    Abstract: Preconcentrates comprising a fatty acid oil mixture and at least one surfactant, and methods and uses thereof are disclosed. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: July 26, 2022
    Assignee: ProNova BioPharma Norge AS
    Inventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Jo Erik Johnsrud Klaveness
  • Patent number: 11389430
    Abstract: A method of treating a hyperoxia induced disease or disorder associated with GSNO deficiency in a subject in need thereof includes administering to the subject a therapeutically effective amount of GSNO or a GSNO promoting agent.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: July 19, 2022
    Inventors: Thomas M. Raffay, Benjamin M. Gaston
  • Patent number: 11364247
    Abstract: The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: June 21, 2022
    Assignee: BIAL-PORTELA & CA S.A.
    Inventors: José Luís de Almeida, Patrício Manuel Vieira Araújo Soares da Silva
  • Patent number: 11364209
    Abstract: The present invention provides methods and compositions for treating atopic dermatitis by cyclohexenone compounds.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: June 21, 2022
    Assignee: Golden Biotechnology Corporation
    Inventors: Sheng-Yung Liu, Chih-Ming Chen
  • Patent number: 11364196
    Abstract: The present invention relates to novel oral spray formulations of Levothyroxine. Further the invention also describes process for preparing such formulations.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: June 21, 2022
    Inventors: Kocherlakota Chandrashekhar, Banda Nagaraju
  • Patent number: 11357776
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: June 14, 2022
    Inventors: Brian North, Steven Quayle
  • Patent number: 11358955
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: June 14, 2022
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • Patent number: 11344522
    Abstract: The present invention generally relates to the field of dietary therapies for treating disorders associated with mitochondrial dysfunction, including epilepsy.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: May 31, 2022
    Assignees: Vitaflow (International) Ltd, UCL Business PLC
    Inventors: Maura O'Donnell, Bridget Lambert, Patricia Wallis, Patricia Rutherford, Simon Heales, Sean-David Hughes, Helen Cross, Simon Eaton
  • Patent number: 11339154
    Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N oxides, and salts thereof, wherein A, X1, X2, X3 and R2 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: May 24, 2022
    Assignee: FMC Corporation
    Inventors: Wenming Zhang, Moumita Kar, Kasinath Sana
  • Patent number: 11331303
    Abstract: Described herein are methods for treating one or more skin conditions by administering, via the sublingual or buccal route, a composition comprising substituted or unsubstituted diindolylmethane. In particular, methods are provided for improving the bioavailability and pharmacokinetic parameters of substituted or unsubstituted diindolylmethane following a sublingual or buccal administration, relative to an oral administration.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 17, 2022
    Inventor: Michael C. Scaife
  • Patent number: 11331309
    Abstract: Compositions suitable for oral use (e.g., oral thin film) containing various excipients and a combination of melatonin, caryophyllene, GABA, L-theanine, and vitamin B6. Methods of using the composition, e.g., in the treatment of a sleeping disorder, as well as methods of manufacturing the composition are also included.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: May 17, 2022
    Inventor: Jose Bernardo
  • Patent number: 11331312
    Abstract: The present disclosure describes a compositions and methods for treatment of Hras-driven cancers. Administration of a farnesyltransferase inhibitor, for example, tipifarnib, alone or in combination with a MEK inhibitor can reduce tumor size and tumor growth in cancers such as poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC).
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: May 17, 2022
    Inventors: James A. Fagin, Jeffrey A. Knauf, Brian R. Untch